The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index

Joseph A. Pidala, Betty K. Hamilton, Paul J. Martin, Lynn Onstad, Barry E. Storer, Jeanne Palmer, Amin Alousi, Corey Cutler, Madan H. Jagasia, George L. Chen, Mukta Arora, Mary E. Flowers, Stephanie J. Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In clinical trials of chronic graft-versus-host disease (cGVHD), the need to start a new systemic treatment is considered a treatment failure. A composite endpoint called “failure-free survival” (FFS), where events are initiation of a new systemic cGVHD treatment, recurrent malignancy, and death, has been suggested as a possible long-term indicator of success. The goal of the current study was to identify changes in cGVHD manifestations from baseline to 6 months that could accurately predict subsequent longer-term FFS, thereby making it possible to assess outcomes earlier than would otherwise be possible. We used data from 2 prospective, multicenter, observational studies to develop the cGVHD-FFS index. The cGVHD-FFS index was calculated at 6 months, a typical timepoint for assessment of the primary endpoint of phase II cGVHD trials. Subsequent FFS was only 45% within the next 2 years. We found that changes in the scores for the eyes, joint/fascia, and mouth ulcers from baseline to 6 months were associated with subsequent FFS, but the prognostic accuracy of these changes was not adequate for use in trials. Biomarker studies might help to identify criteria that improve prediction of long-term clinical outcomes in patients with cGVHD.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Graft vs Host Disease
Disease-Free Survival
Survival
Oral Ulcer
Fascia
Treatment Failure
Multicenter Studies
Observational Studies
Joints
Biomarkers
Clinical Trials
Therapeutics
Neoplasms

Keywords

  • Chronic graft-versus-host disease
  • Failure-free survival
  • Prognostic model

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. / Pidala, Joseph A.; Hamilton, Betty K.; Martin, Paul J.; Onstad, Lynn; Storer, Barry E.; Palmer, Jeanne; Alousi, Amin; Cutler, Corey; Jagasia, Madan H.; Chen, George L.; Arora, Mukta; Flowers, Mary E.; Lee, Stephanie J.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Pidala, JA, Hamilton, BK, Martin, PJ, Onstad, L, Storer, BE, Palmer, J, Alousi, A, Cutler, C, Jagasia, MH, Chen, GL, Arora, M, Flowers, ME & Lee, SJ 2019, 'The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.07.040
Pidala, Joseph A. ; Hamilton, Betty K. ; Martin, Paul J. ; Onstad, Lynn ; Storer, Barry E. ; Palmer, Jeanne ; Alousi, Amin ; Cutler, Corey ; Jagasia, Madan H. ; Chen, George L. ; Arora, Mukta ; Flowers, Mary E. ; Lee, Stephanie J. / The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. In: Biology of Blood and Marrow Transplantation. 2019.
@article{7fe20f43fad149ec90ef52c8c6103638,
title = "The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index",
abstract = "In clinical trials of chronic graft-versus-host disease (cGVHD), the need to start a new systemic treatment is considered a treatment failure. A composite endpoint called “failure-free survival” (FFS), where events are initiation of a new systemic cGVHD treatment, recurrent malignancy, and death, has been suggested as a possible long-term indicator of success. The goal of the current study was to identify changes in cGVHD manifestations from baseline to 6 months that could accurately predict subsequent longer-term FFS, thereby making it possible to assess outcomes earlier than would otherwise be possible. We used data from 2 prospective, multicenter, observational studies to develop the cGVHD-FFS index. The cGVHD-FFS index was calculated at 6 months, a typical timepoint for assessment of the primary endpoint of phase II cGVHD trials. Subsequent FFS was only 45{\%} within the next 2 years. We found that changes in the scores for the eyes, joint/fascia, and mouth ulcers from baseline to 6 months were associated with subsequent FFS, but the prognostic accuracy of these changes was not adequate for use in trials. Biomarker studies might help to identify criteria that improve prediction of long-term clinical outcomes in patients with cGVHD.",
keywords = "Chronic graft-versus-host disease, Failure-free survival, Prognostic model",
author = "Pidala, {Joseph A.} and Hamilton, {Betty K.} and Martin, {Paul J.} and Lynn Onstad and Storer, {Barry E.} and Jeanne Palmer and Amin Alousi and Corey Cutler and Jagasia, {Madan H.} and Chen, {George L.} and Mukta Arora and Flowers, {Mary E.} and Lee, {Stephanie J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.07.040",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index

AU - Pidala, Joseph A.

AU - Hamilton, Betty K.

AU - Martin, Paul J.

AU - Onstad, Lynn

AU - Storer, Barry E.

AU - Palmer, Jeanne

AU - Alousi, Amin

AU - Cutler, Corey

AU - Jagasia, Madan H.

AU - Chen, George L.

AU - Arora, Mukta

AU - Flowers, Mary E.

AU - Lee, Stephanie J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In clinical trials of chronic graft-versus-host disease (cGVHD), the need to start a new systemic treatment is considered a treatment failure. A composite endpoint called “failure-free survival” (FFS), where events are initiation of a new systemic cGVHD treatment, recurrent malignancy, and death, has been suggested as a possible long-term indicator of success. The goal of the current study was to identify changes in cGVHD manifestations from baseline to 6 months that could accurately predict subsequent longer-term FFS, thereby making it possible to assess outcomes earlier than would otherwise be possible. We used data from 2 prospective, multicenter, observational studies to develop the cGVHD-FFS index. The cGVHD-FFS index was calculated at 6 months, a typical timepoint for assessment of the primary endpoint of phase II cGVHD trials. Subsequent FFS was only 45% within the next 2 years. We found that changes in the scores for the eyes, joint/fascia, and mouth ulcers from baseline to 6 months were associated with subsequent FFS, but the prognostic accuracy of these changes was not adequate for use in trials. Biomarker studies might help to identify criteria that improve prediction of long-term clinical outcomes in patients with cGVHD.

AB - In clinical trials of chronic graft-versus-host disease (cGVHD), the need to start a new systemic treatment is considered a treatment failure. A composite endpoint called “failure-free survival” (FFS), where events are initiation of a new systemic cGVHD treatment, recurrent malignancy, and death, has been suggested as a possible long-term indicator of success. The goal of the current study was to identify changes in cGVHD manifestations from baseline to 6 months that could accurately predict subsequent longer-term FFS, thereby making it possible to assess outcomes earlier than would otherwise be possible. We used data from 2 prospective, multicenter, observational studies to develop the cGVHD-FFS index. The cGVHD-FFS index was calculated at 6 months, a typical timepoint for assessment of the primary endpoint of phase II cGVHD trials. Subsequent FFS was only 45% within the next 2 years. We found that changes in the scores for the eyes, joint/fascia, and mouth ulcers from baseline to 6 months were associated with subsequent FFS, but the prognostic accuracy of these changes was not adequate for use in trials. Biomarker studies might help to identify criteria that improve prediction of long-term clinical outcomes in patients with cGVHD.

KW - Chronic graft-versus-host disease

KW - Failure-free survival

KW - Prognostic model

UR - http://www.scopus.com/inward/record.url?scp=85071525733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071525733&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.07.040

DO - 10.1016/j.bbmt.2019.07.040

M3 - Article

C2 - 31394265

AN - SCOPUS:85071525733

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -